• NEWCELX. (NCEL)
  • $-- --- (--%)
  • NASDAQ Capital Market
Header science

Products

Innovative Therapies: Leading with IsletRx for Type 1 Diabetes

 

IsletRx

IsletRx is NewcelX’s lead stem-cell-derived therapy designed to restore functional insulin production in individuals with insulin-dependent Type 1 Diabetes. Built on our scalable human pluripotent stem cell (hPSC) platform, IsletRx integrates advanced cell differentiation, purification, and delivery strategies aimed at enabling durable graft function while reducing or potentially eliminating the need for chronic immunosuppression. Supported by compelling preclinical data and ongoing translational development, IsletRx represents the company’s primary focus and a central pillar of its long-term value creation strategy.

AstroRx®

AstroRx® is an advanced cell therapy for amyotrophic lateral sclerosis (ALS) designed to support and protect motor neurons. The program has demonstrated encouraging results in a completed Phase 1/2a clinical trial and provides important clinical, manufacturing, and regulatory validation for NewcelX’s cell therapy platform and development capabilities.

DOXA

DOXA is a discovery-stage small-molecule program targeting the orexin pathway, a key regulator of metabolic function, energy balance, and neurological signaling. This novel API platform broadens NewcelX’s therapeutic scope across CNS and metabolic indications while reinforcing the scientific depth underlying its core diabetes-focused strategy.